{"commentary":{"count":45,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":45},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00352846\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT00352846","nct_id":"NCT00352846","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct00352846. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Oral Vitamin D 400 mg daily + Calcium 1200 mg daily","label":"Vitamin D + Calcium Carbonate","type":"EXPERIMENTAL"},{"description":"Oral Vitamin D 400 mg daily and Calcium 1200 mg daily; Zoledronic Acid 4 mg/m\\^2 intravenous at baseline and 6 months.","label":"Vitamin D + Calcium Carbonate + Zoledronic Acid","type":"EXPERIMENTAL"}],"collaborators":["Novartis"],"completion_date":{"date":"2011-09","type":"ACTUAL"},"conditions":["Non-Hodgkin's Lymphoma","Lymphoma"],"enrollment":{"count":135,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Zoledronic Acid","type":"DRUG"},{"name":"Vitamin D","type":"DRUG"},{"name":"Calcium Carbonate","type":"DRUG"}],"last_update":"2013-07-02","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss in Non-Hodgkin's Lymphoma Patients Receiving Chemotherapy","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2011-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage Change in Bone Mineral Density (BMD) T-Score From Baseline to 12 Months","timeFrame":"From baseline to 12 Months"}],"references":[{"citation":"Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):99-105. doi: 10.1016/j.clml.2012.11.002. Epub 2012 Dec 29.","pmid":"23276888","type":"DERIVED"}],"start_date":{"date":"2006-01"},"study_type":"INTERVENTIONAL","title":"Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss","url":"https://clinicaltrials.gov/study/NCT00352846"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct00352846"}